News

SBM Offshore's Supervisory Board Sees Notable Changes Ahead

SBM Offshore's Supervisory Board Sees Notable Changes Ahead

SBM Offshore's Supervisory Board Changes

SBM Offshore has confirmed a recent update regarding its Supervisory Board, announcing that Bernard Bajolet will step down following the upcoming Annual General Meeting. After serving diligently for seven years, Bajolet's decision to resign is prompted by personal reasons. However, he is expected to continue contributing to the company in an advisory capacity, ensuring that his insights and experience remain accessible to the team.

Appreciations from Leadership

Roeland Baan, CEO of SBM Offshore, expressed gratitude towards Bajolet, emphasizing the significant value he brought to the company during his tenure as a member of the Supervisory Board. Baan noted, "We thank Bernard for his valuable contribution to the Company as Supervisory Board member and look forward to his continued involvement as advisor." This sentiment reflects the collaborative spirit and appreciation that permeates the culture at SBM Offshore.

About SBM Offshore

SBM Offshore is recognized as a leading expert in deepwater ocean-infrastructure. The company excels in providing solutions related to the design, construction, installation, and operation of offshore floating facilities. Their commitment to fostering a sustainable future is evident through their focus on cleaner and more efficient energy production, which plays a crucial role in the global shift towards a just transition. With a dedicated workforce of over 7,400 professionals worldwide, SBM Offshore continues to advance its mission of balancing ocean protection with the need for progress.

Innovative Contributions to the Blue Economy

The company's pioneering efforts unlock new markets within the blue economy, providing innovative strategies that address the demands of a changing economic landscape. By integrating responsible partnerships and sustainable practices, SBM Offshore is positioned as a leader aiming for a brighter ecological future.

Upcoming Financial Calendar

SBM Offshore has outlined its key financial dates for stakeholders, which include:

  • Full Year 2024 Earnings – February 20, 2025
  • Annual General Meeting – April 9, 2025
  • First Quarter 2025 Trading Update – May 15, 2025
  • Half Year 2025 Earnings – August 7, 2025
  • Third Quarter 2025 Trading Update – November 13, 2025

Contact Information

For any inquiries, stakeholders can reach out via the following contacts:

Investor Relations

Wouter Holties
Corporate Finance & Investor Relations Manager

Phone: +31 (0)20 236 32 36
Email: wouter.holties@sbmoffshore.com

Media Relations

Giampaolo Arghittu
Head of External Relations

Phone: +31 (0)6 212 62 333 / +39 33 494 79 584
Email: giampaolo.arghittu@sbmoffshore.com

Frequently Asked Questions

What prompted Bernard Bajolet to step down from the board?

Bernard Bajolet’s decision to resign was based on personal reasons, although he will continue in an advisory role.

How long did Bajolet serve on the Supervisory Board?

He served on the Supervisory Board for seven years.

What is the primary focus of SBM Offshore?

SBM Offshore focuses on the design, construction, and operation of offshore floating facilities to support cleaner and more efficient energy production.

How does SBM Offshore contribute to sustainability?

The company aims to deliver innovative solutions that balance ocean protection with economic progress, thus contributing to sustainability in the blue economy.

Where can I find more information about SBM Offshore?

You can find additional information on their official website at www.sbmoffshore.com.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 26

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 35

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 24

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 35

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 34

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 37

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading

Top 5 Most Recently Viewed Articles

Embla Medical hf Reports Strong Q2 2025 Financial Performance

Updated Category News Views 203

Embla Medical hf's Interim Report for Q2 2025 Announcement No. 33/2025 Interim Report Q2 2025 Embla Medical hf has recently published its interim report for the second quarter of 2025, revealing encouraging financial results. The organization remains committed to enhancing mobility solutions through innovative offerings in prosthetics and orthotics. Strong Sales Growth...

Continue Reading
Fly-E Group Faces Important Class Action Deadline for Investors

Updated Category News Views 185

Fly-E Group Update: Important Class Action Deadline Attention investors of Fly-E Group, Inc. If you purchased securities between July 15 and August 14, 2025, this is vital news for you. As we approach a crucial lead plaintiff deadline on November 10, 2025, the time to act is now. Understanding the Class Action The upcoming class action lawsuit revolves around Fly-E's...

Continue Reading
Royal Unibrew Posts Impressive Earnings Growth in Q3 2024

Updated Category News Views 173

Royal Unibrew's Remarkable Performance in Q3 2024 Royal Unibrew has demonstrated exceptional growth during the third quarter of 2024. The key highlights from this trading statement reveal a robust progression in organic volume and net revenue, paving the way for a bright future for the company. Strong Growth Metrics Organic Volume and Revenue Increases During Q3 2024,...

Continue Reading
Examining Medtronic PLC's Short Selling Trends and Insights

Updated Category News Views 184

Understanding Medtronic PLC's Short Interest Medtronic PLC (NYSE: MDT) has recently experienced a significant rise in its short interest as a percentage of float, currently at 17.56%. This increase signals a growing concern among investors, as the total number of shares sold short has reached 19.72 million, accounting for 1.54% of all available shares for trading. With...

Continue Reading
Palatin Technologies Announces Breakthrough in Obesity Management

Updated Category News Views 138

Positive Developments in Appetite Suppression Research Palatin Technologies, Inc. (NYSE American: PTN), a leading biopharmaceutical firm known for pioneering medications based on the melanocortin receptor system, has recently reported encouraging results concerning appetite suppression from its Phase 2 obesity study involving bremelanotide and tirzepatide. This...

Continue Reading